Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Filippo Bagnoli"'
Autor:
Maria Moscvin, Christine Ivy Liacos, Tianzeng Chen, Foteini Theodorakakou, Despina Fotiou, Shahrier Hossain, Sean Rowell, Houry Leblebjian, Eileen Regan, Peter Czarnecki, Filippo Bagnoli, Niccolo’ Bolli, Paul Richardson, Helmut G. Rennke, Meletios A. Dimopoulos, Efstathios Kastritis, Giada Bianchi
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leadi
Externí odkaz:
https://doaj.org/article/3db82b86263f49e39f4001b810e51940
Autor:
Matteo C. Da Vià, Bachisio Ziccheddu, Akihiro Maeda, Filippo Bagnoli, Giulia Perrone, Niccolò Bolli
Publikováno v:
HemaSphere, Vol 4, Iss 6, p e502 (2020)
Abstract. The knowledge of cancer origin and the subsequent tracking of disease evolution represent unmet needs that will soon be within clinical reach. This will provide the opportunity to improve patient's stratification and to personalize treatmen
Externí odkaz:
https://doaj.org/article/17a6dd0a5aed464b87896560ed433e31
Autor:
Arturo Bonometti, Jessica Gliozzo, Chiara Moltrasio, Filippo Bagnoli, Luigia Venegoni, Emanuela Passoni, Marco Paulli, Emilio Berti
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 4, Pp 450-451 (2019)
Externí odkaz:
https://doaj.org/article/7fcdb2eadf964606b3a08ce691001aae
Autor:
Anna Guidetti, Anna Dodero, Alice Lorenzoni, Sara Pizzamiglio, Giovanni Argiroffi, Annalisa Chiappella, Filippo Bagnoli, Vincenzo Marasco, Cristiana Carniti, Chiara Monfrini, Ettore Seregni, Martina Pennisi, Paolo Verderio, Alessandra Alessi, Paolo Corradini
Publikováno v:
Cancer. 129:255-263
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d17459f07376d47d811e32402d8bbbf
https://doi.org/10.1002/cncr.34532
https://doi.org/10.1002/cncr.34532
Autor:
Fabio Serpenti, Anushka Shankar, Nicolo' Rampi, Cristina Mocellin, Cecilia Fidanza, Maria Cecilia Goldaniga, Giorgia Saporiti, Matteo Claudio Da Via, Giulia Galassi, Loredana Pettine, Filippo Bagnoli, Niccolo Bolli, Luca Baldini, Alessandra Pompa, Francesco Onida
Publikováno v:
Blood. 140:12576-12577
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55c7ebca9eee0e3622bb47cc527a60ee
https://doi.org/10.1182/blood-2022-169454
https://doi.org/10.1182/blood-2022-169454
Autor:
Francesca Cavallaro, Francesco Versino, Fabio Serpenti, Simona Iacobelli, Silvia Alberti Violetti, Giorgia Saporiti, Maria Goldaniga, Giulia Galassi, Filippo Bagnoli, Nicolo' Rampi, Kordelia Barbullushi, Alessandro Bosi, Giulio Cassanello, Gabriele Simontacchi, Concetta Schiavone, Luca Baldini, Emilio Berti, Francesco Onida
Publikováno v:
Blood. 140:7721-7722
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc77ecf7bf35e2222841bdb222456604
https://doi.org/10.1182/blood-2022-169660
https://doi.org/10.1182/blood-2022-169660
Cutaneous‐group histiocytoses associated with myeloid malignancies: A systematic review of 102 cases
Publikováno v:
Australasian Journal of Dermatology. 62
Background Histiocytoses are haematological disorders of bone marrow origin that share many biological and clinical features with haematological neoplasms. The association between histiocytoses of the cutaneous-group and myeloid malignancies is a poo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::117934fed4f5aaea2f7b9d47eeb9b8ed
https://doi.org/10.1111/ajd.13491
https://doi.org/10.1111/ajd.13491
Autor:
Valentina Monti, Maria Luisa Moiraghi, Niccolo Bolli, Filippo Bagnoli, Maria Adele Testi, Sabine Stioui, Giancarlo Pruneri, Laura Vittoria
Publikováno v:
Tumori. 106(6)
Introduction: Myeloid malignancies are associated with a number of recurrent and sporadic rearrangements that may be oncogenic by ensuring growth advantage and/or increased survival. t(3;3)(q21;q26) has been recognized as a recurrent abnormality in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::991f19ee26e816c8d5d9ec32770dcaa7
https://pubmed.ncbi.nlm.nih.gov/32831008
https://pubmed.ncbi.nlm.nih.gov/32831008
Autor:
Bachisio Ziccheddu, Marialuisa Sensi, Paolo Corradini, Even H Rustad, Cristiana Carniti, Niccolo Bolli, Giulia Biancon, Efstathios Kastritis, Francesco Maura, Meletios A. Dimopoulos, Carolina Terragna, Matteo Dugo, Filippo Bagnoli, Tina Bagratuni, Andrea Devecchi, Loris De Cecco, Marina Martello, Michele Cavo, Vittorio Montefusco, Chiara De Philippis
Publikováno v:
Blood Advances
In multiple myeloma, novel treatments with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) have prolonged survival but the disease remains incurable. At relapse, next-generation sequencing has shown occasional mutations of drug target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de58e008f426de6be4f829fcdb962fd8
Autor:
Paolo Corradini, Chiara Monfrini, Federica Sorà, Stefania Bramanti, Filippo Bagnoli, Anna Guidetti, Vanessa Aragona, Cristiana Carniti, Anna Dodero, Annalisa Chiappella, Pier Luigi Zinzani, Matteo Carrabba, Anna Maria Barbui
Publikováno v:
Blood. 136:12-13
Background: Eighty-five percent of PMBCL are cured by standard therapy, but the outcome of refractory/relapsed (R/R) PMBCL is very poor. Checkpoint inhibitors (CPIs) have shown promising activity in relapsed PMBCL. Axibactagene ciloleucel (axi-cel) C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64b2d71f260b5e34055ff48b16f4ed33
https://doi.org/10.1182/blood-2020-140054
https://doi.org/10.1182/blood-2020-140054